News
Roivant wins FDA approval for first targeted dermatomyositis...
Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.
Market Access
Biotech funding has returned. The bar has moved with it.
For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
News
ViiV wins US approval for HIV treatment in newborn babies
The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg.
News
Expanded US Imaavy approval first ever for wAIHA
The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).
News
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe
Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
